Skip to main content
Clinical Trials/NCT01082744
NCT01082744
Completed
Phase 3

Thoracic Paravertebral Block: a Comparative Study of Ropivacaine With Ropivacaine and Sufentanil for Treating Pain After Video-assisted Thoracic Surgery.

Hospices Civils de Lyon1 site in 1 country90 target enrollmentMarch 1, 2010

Overview

Phase
Phase 3
Intervention
Ropivacaine
Conditions
Pain, Postoperative
Sponsor
Hospices Civils de Lyon
Enrollment
90
Locations
1
Primary Endpoint
morphine consumption during the first 48 hours
Status
Completed
Last Updated
4 months ago

Overview

Brief Summary

The use of paravertebral catheters is a recommended technique to achieve postoperative analgesia after thoracic surgery. To date there is no consensus on which drug regime (local anesthetics with or without opioid) is best. The aim of this prospective clinical trial is to determine wether the use of ropivacaine and sufentanil injected through a thoracic paravertebral catheter results in decreased acute postoperative pain compared with plain ropivacaine in patients after thoracoscopic lung surgery.

Registry
clinicaltrials.gov
Start Date
March 1, 2010
End Date
December 1, 2014
Last Updated
4 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patient scheduled for planned video-assisted thoracic surgery
  • Patient that consent to participate
  • Planned placement of paravertebral catheter
  • Patient having a medical insurance

Exclusion Criteria

  • Patient less than 18 years
  • Refusal to participate
  • Known pregnancy
  • Known allergies to local anesthetics, sufentanil and /or to iodinated contrast material
  • Intolerance to sufentanil and/or morphine
  • Chronic consumption of opiates
  • Preoperative chronic pain syndrome
  • Patient having a contraindication to placement of paravertebrtal catheter

Arms & Interventions

Continuous paravertebral block with ropivacaine

Intervention: Ropivacaine

Continuous paravertebral block with ropivacaine and sufentanil

Intervention: Ropivacaine + Sufentanil

Outcomes

Primary Outcomes

morphine consumption during the first 48 hours

Time Frame: 48 hours

Secondary Outcomes

  • Acute pain(48 hours)
  • Biological measurements(48 hours)
  • Patient satisfaction(48 hours)
  • Chronic pain(3 and 6 monthes)

Study Sites (1)

Loading locations...

Similar Trials